

CSD/NSE&BSE/RPT/2022-23 May 21, 2022

To The Manager Department of Corporate Services BSE Limited 25th Floor, P. J. Towers, Dalal Street, Mumbai - 400 001 To The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions and balances for the half-year ended 31<sup>st</sup> March, 2022.

This is for your information and record.

Thanking you, Yours faithfully, For **Suven Pharmaceuticals Limited** 

K. Hanumantha Rao Company Secretary

Encl: as above

## **Suven Pharmaceuticals Limited**

Registered Office: # 8-2-334 | SDE Serene Chambers | 3rd Floor | Road No.5 Avenue 7 | Banjara Hills | Hyderabad - 500034 | Telangana | India | CIN: L24299TG2018PLC128171 Tel: 91 40 2354 9414 /1142 /3311 | Fax: 91 40 2354 1152 | Email: info@suvenpharm.com | www.suvenpharm.com

																	(	Rs. in lakhs)	
SI.	Details of the party (listed Details of the counterparty				Type of related	Value of the	Value of	In case monies are due		Additional disclosure of related party transactions - applicable only in case the related party									
No	entity /subsidiary) e	entering				party transaction	related party	transactio	to either party as a		transaction relates to loans, inter-corporate deposits, advances or investments made or given by							or given by	
	into the transac	tion					transaction as	n during	result of the transaction		the listed entity/subsidiary. These details need to be disclosed only once, during the reporting							e reporting	
						(see Note 5)	approved by	the	(see Note 1)		period when such transaction was undertaken.								
							the audit	reporting			In case any finar	ncial ind	ebtedness	Details of th	e loans, in	ter-corpora	ite deposits, a	advances or	
							committee	period			is incurred to make or give loans,			Details of the loans, inter-corporate deposits, advances or investments					
							(see Note 6a)	(see Note			inter-corporate deposits, advances								
							(,	6b)			or investments	,	,						
	Name	PAN	Name	PAN	Relationship of the			,	Opening	Closing	Nature of	Cost	Tenure	Nature	Interest	Tenure	Secured/	Purpose for	
					counterparty with				balance	balance	indebtedness	(see		(loan/	Rate		unsecured	which the	
					the listed entity or						(loan/ issuance	Not		advance/	(%)			funds will	
					its subsidiary						of debt/ any	e 7)		intercorpor	(,,,)			be utilised	
					its substatut y						other etc.)	077		ate				by the	
											other etc.y			deposit/				ultimate	
														investment				recipient of	
														investment				funds (end-	
																		usage)	
1	Suven		Jasti Property and									1					1	usuge/	
-	Pharmaceuticals		Equity Holdings		Trustee Company	Dividend paid	Not	4,581.90											
	Ltd.		Private Limited				applicable	.,002.00											
2					Company under the														
-	Suven		Suven Life		Control of Key	Lease Rental													
	Pharmaceuticals		Sciences Limited		Managerial	Income	109.79 p.a.	55.41											
	Ltd.		Sciences Einneu		Personnel	meonie													
3					Company under the														
5	Suven		Suven Life		Control of Key	Rendering Service													
	Pharmaceuticals		Sciences Limited		Managerial	charges		365.09											
	Ltd.		Sciences Linnieu		Personnel	charges	2500.00 per												
1					Company under the		Financial Year												
-	Suven		Suven Life		Control of Key														
	Pharmaceuticals		Sciences Limited		Managerial	Sale of material		126.22											
	Ltd.		Sciences Linnieu		Personnel														
5	Suven													+			+		
J	Pharmaceuticals		Suven Pharma		Wholly Owned	Disinvestment of	Not	12,697.44	24557.68	11860.24									
	Ltd.		lnc.,		Subsidiary	Capital	applicable	12,037.44	27337.00	11000.24									
6	Suven																		
0	Pharmaceuticals		Suven Pharma		Wholly Owned	Dividend received	Not	11,752.46											
	Ltd.		Inc.,		Subsidiary		applicable	11,732.40											
7	Suven		Mr.			Short term											1	-	
,	Pharmaceuticals		Venkateswarlu	1	Key Managerial	employee	757.23	757.23											
	Ltd.		Jasti		Personnel	benefits	/5/.23	151.23											
0			Mr.			Denenits													
8	Suven				Key Managerial	Dividond raid	Not	0.00											
	Pharmaceuticals		Venkateswarlu	1	Personnel	Dividend paid	applicable	0.06											
0	Ltd.	_	Jasti			Chart tan													
9	Suven		Mars Kalan di La di		Relative of Key	Short term	101.07	4 6 4 6 -											
	Pharmaceuticals		Mrs Kalyani Jasti	1	Managerial	employee	161.67	161.67											
	Ltd.				Personnel	benefits													

																	(	Rs. in lakhs)
SI.	Details of the party (listed Details of the co			f the co	unterparty	Type of related	Value of the	Value of	In case monies are due		Additional disclosure of related party transactions - applicable only in case the related party							
No	entity /subsidiary) entering into the transaction					party transaction (see Note 5)	related party transaction as	transactio n during	to either party as a result of the transaction		transaction relates to loans, inter-corporate deposits, advances or investments made or given by							
											the listed entity/subsidiary. These details need to be disclosed only once, during the reporting							e reporting
							approved by the audit	the	(see Note 1)		period when such transaction was undertaken.							
								reporting			In case any finan	In case any financial indebtedness Details of the loans, inter-corporate deposits, advances of						
							committee (see Note 6a)	period (see Note 6b)			is incurred to make or give loans, inter-corporate deposits, advances or investments			investments				
	Name	PAN	Name	PAN	Relationship of the				Opening	Closing	Nature of	Cost	Tenure	Nature	Interest	Tenure	Secured/	Purpose for
					counterparty with				balance	balance	indebtedness	(see		(loan/	Rate		unsecured	which the
					the listed entity or						(loan/ issuance	Not		advance/	(%)			funds will
					its subsidiary						of debt/ any	e 7)		intercorpor	. ,			be utilised
					,						other etc.)			ate				by the
														deposit/				ultimate
														investment				recipient of
																		funds (end-
																		usage)
10	Suven				Relative of Key		Not											
	Pharmaceuticals		Mrs Kalyani Jasti		Managerial	Dividend paid	Not	0.06										
	Ltd.				Personnel		applicable											
11	Suven		Mrs Sudharani		Relative of Key		Not											
	Pharmaceuticals		Jasti		Managerial	Dividend paid	applicable	0.06										
	Ltd.		Jasu		Personnel		applicable											
12	Suven				Relative of Key		Net											
	Pharmaceuticals		Mrs Madhavi Jasti		Managerial	Dividend paid	Not	0.06										
	Ltd.				Personnel		applicable											
13	Suven				Relative of Key		Not											
	Pharmaceuticals		Mrs Sirisha Jasti		Managerial	Dividend paid	applicable	0.06										
	Ltd.				Personnel		applicable											
14	Suven				Key Managerial		Not											
	Pharmaceuticals		Mr. P. Subba Rao		Personnel	Dividend paid	applicable	3.58										
	Ltd.				Personner		applicable											
15	Suven		Mr. D. G. Prasad		Key management	Sitting fee	Not	3.55										
	Pharmaceuticals				personnel		applicable											
	Ltd.																	
16	Suven		Mr. S		Key Managerial	Sitting fee	Not	1.78										
	Pharmaceuticals		Chandrasekhar		Personnel		applicable											
	Ltd.																	
17	Suven		Mrs. Deepanwita		Key Managerial	Sitting fee	Not	2.22										
	Pharmaceuticals		Chattopadhyay		Personnel		applicable											
	Ltd.																	
18	Suven		Mr. J. V. Ramudu		Key Managerial	Sitting fee	Not	3.78										
	Pharmaceuticals				Personnel		applicable											
	Ltd.																	
19	Suven		Mr. V. Sambasiva		Key Managerial	Sitting fee	Not	2.89										
	Pharmaceuticals		Rao		Personnel		applicable											
	Ltd.																	1